Literature DB >> 22094024

Primary sclerosing cholangitis and disease distribution in inflammatory bowel disease.

Aoibhlinn O'Toole1, Alaa Alakkari, Denise Keegan, Glen Doherty, Hugh Mulcahy, Diarmuid O'Donoghue.   

Abstract

BACKGROUND & AIMS: The relationship between site of intestinal inflammation and primary sclerosing cholangitis (PSC) development in inflammatory bowel disease (IBD) has not been studied extensively, but may be important in understanding the pathogenesis of PSC. We aimed to determine patterns of disease distribution in IBD patients with and without PSC.
METHODS: We performed a 2-part study involving the following: (1) 2754 IBD patients and (2) 82 separate PSC patients attending the Irish National Liver Transplant Unit.
RESULTS: Fifty-nine of 2708 (2.2%) IBD patients had PSC. In ulcerative colitis patients, PSC incidence increased with increasing colonic involvement (P = .001) and was relatively rare in those without total colitis. Thirteen Crohn's disease patients had PSC, none with isolated small-bowel disease had PSC (P = .03). In study 2, the majority of ulcerative colitis patients with PSC had total colitis, whereas the remainder had disease extending at least to the left colon. In addition, all 10 PSC patients with Crohn's disease had colonic involvement.
CONCLUSIONS: An inflamed colon, but not small bowel, is important in PSC development and it is possible that bacterial translocation and subsequent portal bacteremia is important in PSC development in IBD. Copyright Â
© 2012 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22094024     DOI: 10.1016/j.cgh.2011.11.010

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  24 in total

1.  MR elastography in primary sclerosing cholangitis: correlating liver stiffness with bile duct strictures and parenchymal changes.

Authors:  Candice A Bookwalter; Sudhakar K Venkatesh; John E Eaton; Thomas D Smyrk; Richard L Ehman
Journal:  Abdom Radiol (NY)       Date:  2018-12

2.  Impact of Crohn's Disease Duration on the Risk of Cholangiocarcinoma in Patients With Primary Sclerosing Cholangitis.

Authors:  De-Jun Cui; Xun Zhao; Mei Hu
Journal:  Am J Gastroenterol       Date:  2017-01       Impact factor: 10.864

3.  Non-invasive urinary metabolomic profiles discriminate biliary atresia from infantile hepatitis syndrome.

Authors:  Wei-Wei Li; Yan Yang; Qi-Gang Dai; Li-Li Lin; Tong Xie; Li-Li He; Jia-Lei Tao; Jin-Jun Shan; Shou-Chuan Wang
Journal:  Metabolomics       Date:  2018-06-21       Impact factor: 4.290

Review 4.  Distinctive inflammatory bowel disease phenotype in primary sclerosing cholangitis.

Authors:  A Boudewijn de Vries; Marcel Janse; Hans Blokzijl; Rinse K Weersma
Journal:  World J Gastroenterol       Date:  2015-02-14       Impact factor: 5.742

Review 5.  The IBD and PSC Phenotypes of PSC-IBD.

Authors:  Amanda Ricciuto; Binita M Kamath; Anne M Griffiths
Journal:  Curr Gastroenterol Rep       Date:  2018-03-28

Review 6.  Contribution of the Intestinal Microbiome and Gut Barrier to Hepatic Disorders.

Authors:  Daniel M Chopyk; Arash Grakoui
Journal:  Gastroenterology       Date:  2020-06-20       Impact factor: 22.682

7.  Evolving strategies to reduce colectomy rates in primary sclerosing cholangitis-inflammatory bowel disease: clinical remission of corticosteroid refractory colitis post-liver transplant with vedolizumab.

Authors:  Saqib Mumtaz; Jason Goh; Gideon M Hirschfield; James Ferguson; Sheldon C Cooper
Journal:  Frontline Gastroenterol       Date:  2016-08-05

Review 8.  Primary sclerosing cholangitis: diagnosis, prognosis, and management.

Authors:  Siddharth Singh; Jayant A Talwalkar
Journal:  Clin Gastroenterol Hepatol       Date:  2013-02-27       Impact factor: 11.382

9.  Characterization of the gut microbiota in patients with primary sclerosing cholangitis compared to inflammatory bowel disease and healthy controls.

Authors:  Samaneh Ostadmohammadi; Masoumeh Azimirad; Hamidreza Houri; Kaveh Naseri; Ehsan Javanmard; Hamed Mirjalali; Abbas Yadegar; Amir Sadeghi; Hamid Asadzadeh Aghdaei; Mohammad Reza Zali
Journal:  Mol Biol Rep       Date:  2021-07-25       Impact factor: 2.316

Review 10.  Mechanisms of tissue injury in autoimmune liver diseases.

Authors:  Evaggelia Liaskou; Gideon M Hirschfield; M Eric Gershwin
Journal:  Semin Immunopathol       Date:  2014-08-01       Impact factor: 9.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.